October 30, 2003
Masur
Auditorium, National Institutes of Health
Bethesda, MD
The iSBTc has held two seminal workshops in the last two years, the first on the NIH campus in 2001 on Immunologic Monitoring and the second in La Jolla, CA, in 2002 on Angiogenesis. The third workshop in this series launched with a limited registration on the NIH campus. This workshop reviewed these six different areas central to modern cancer research through group discussions and a poster session and, within which, focused activities lead to enhanced drug discovery success. These include: 1] proteomics, 2] high content screening, 3] Taqman/transcriptome analysis of the peripheral blood, 4] genomic/transcriptome analysis of tumors, 5] immunohistochemistry of immune cells within the tumor and 6] immune polymorphisms [KIR, LIR, cytokines, etc]. iSBTc brought individuals together from the NIH and FDA, extramural academia, and the pharmaceutical industry/biotechnology sector to consider the current state of the art and strategies to more rapidly advance this area of research and development. To distinguish it from the first workshop which focused on readouts of direct immunologic effects of treatment, this workshop focused on factors which were direct reflections of tumor volume or prognosis. Published output from this Workshop appeared in the Journal of Immunotherapy, the official journal of iSBTc, in early 2005.
